Search results
Results from the Tech24 Deals Content Network
One week ago, Stifel analyst Derek Archila reiterated his "buy" rating on anti-cholesterol drugmaker Amarin (AMRN). He did this partly because he liked how Amarin's Q2 earnings report showed sales ...
Amarin Corporation. Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. [1] The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Amarin (AMRN) closed at $17.90 in the latest trading session, marking a -0.11% move from the prior day.
Barely a month ago, investors of Amarin (AMRN) were left dismayed following a lost patent trial against two generic drug makers seeking to sell their own versions of Amarin’s high triglycerides ...
The Dow Jones Industrial Average (DJIA), Dow Jones, or simply the Dow (/ ˈdaʊ /), is a stock market index of 30 prominent companies listed on stock exchanges in the United States.
The Nasdaq Stock Market (/ ˈnæzdæk / ⓘ; National Association of Securities Dealers Automated Quotations) is an American stock exchange based in New York City. It is the most active stock trading venue in the U.S. by volume, [3] and ranked second on the list of stock exchanges by market capitalization of shares traded, behind the New York ...
Amarin Plc (NASDAQ: AMRN) Q2 2024 Earnings Call Jul 31, 2024, 8:00 a.m. ET
For premium support please call: 800-290-4726 more ways to reach us